Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-Current Deffered Revenue: 2022-2025

Historic Non-Current Deffered Revenue for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to $31.8 million.

  • Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue rose 169.33% to $31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year increase of 169.33%. This contributed to the annual value of $31.8 million for FY2024, which is 166.11% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue stood at $31.8 million, which was down 0.00% from $31.8 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue ranged from a high of $31.8 million in Q4 2024 and a low of $11.8 million during Q2 2024.
  • Its 3-year average for Non-Current Deffered Revenue is $19.2 million, with a median of $12.0 million in 2023.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue dropped by 16.38% in 2023 and then surged by 169.61% in 2025.
  • Quarterly analysis of 4 years shows Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue stood at $12.0 million in 2022, then decreased by 0.38% to $12.0 million in 2023, then surged by 166.11% to $31.8 million in 2024, then skyrocketed by 169.33% to $31.8 million in 2025.
  • Its last three reported values are $31.8 million in Q3 2025, $31.8 million for Q2 2025, and $31.8 million during Q1 2025.